Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls
01:02pm, Tuesday, 15'th Jun 2021
The markets were lower across the board on Tuesday afternoon. All eyes on Wall Street are focused on the two-day Federal Reserve meeting, which began Tuesday, as many are waiting to hear how the narra
uniQure: Biding Time Turns To Buying Time
09:17am, Monday, 14'th Jun 2021
The risk-adjusted value of the CSL Behring collaboration is well in excess of the current enterprise value. Cash now represents over 4 years of runway reducing the risk of dilution.
UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June
10:31am, Wednesday, 02'nd Jun 2021
~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~
uniQure to Participate in Multiple Upcoming Industry Conferences in June
07:34am, Wednesday, 02'nd Jun 2021
~ uniQure to host virtual Research & Development Day on June 22, 2021 ~ ~ uniQure to host virtual Research & Development Day on June 22, 2021 ~
DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged
11:48am, Thursday, 27'th May 2021
The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial evaluating UniQure NV's (NASDAQ: QURE) AMT
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease
07:05am, Thursday, 27'th May 2021
Independent Data Safety Monitoring Board Recommends Proceeding with Second, Higher-Dose Cohort Independent Data Safety Monitoring Board Recommends Proceeding with Second, Higher-Dose Cohort
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
09:01am, Monday, 10'th May 2021
uniQure (QURE) delivered earnings and revenue surprises of -2.25% and -89.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
07:05am, Monday, 10'th May 2021
~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~
Why Moderna, uniQure And Novavax Are Moving Today
10:46am, Thursday, 06'th May 2021
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
07:05am, Thursday, 06'th May 2021
KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QUR
uniQure to Participate in Multiple Upcoming Industry Conferences in May
07:05am, Monday, 03'rd May 2021
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sever
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
07:05am, Wednesday, 28'th Apr 2021
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sev
Strength Seen in uniQure (QURE): Can Its 8.3% Jump Turn into More Strength?
02:17pm, Tuesday, 27'th Apr 2021
uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
